ORLANDO, Fla. ― The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, ...
Vivace said the data from its Phase I trial (NCT04665206) showed that its lead candidate VT3989 had achieved durable anti-tumor responses in patients with advanced malignant mesothelioma and other ...
JUPITER, FL - May 25, 2016 - Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found that one of the most widely prescribed pain and anti-inflammation drugs slows the ...
Scientists have found that one of the most widely prescribed pain and anti-inflammation drugs slows the growth rate of a specific kind of cancer in animal models and suggests the medication could have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback